Connor et al. molecularly characterize primary and metastatic PDAC and show conserved alterations between primary and metastatic lesions. Clinical features outperform molecular alterations in survival analyses, but cell cycle progression and hypoxia signatures may inform clinical practice.
from Cancer Cell http://bit.ly/2B2TBxi
from Cancer Cell http://bit.ly/2B2TBxi